title: Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
abstract: The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer. The trial randomized 2,035 subjects to receive either placebo, celecoxib 200 mg twice daily, or celecoxib 400 mg twice daily. The primary study safety and efficacy analyses involved 3 years of treatment. The results showed significant antitumor effect but also indicated increased cardiovascular adverse events in patients treated with celecoxib compared with placebo. A total of 933 patients participated in an extension of the Adenoma Prevention with Celecoxib Trial, with a planned total treatment and surveillance duration of 5 years. Study medication was stopped early, resulting in a median treatment duration of 3.1 years for those with a year 5 colonoscopy. Patients treated on the placebo arm had a cumulative adenoma incidence of 68.4% over 5 years of observation. This figure was 59.0% (P < 0.0001) for those receiving low-dose celecoxib, and 60.1% (P < 0.0001) for those receiving high-dose celecoxib. The cumulative incidence of advanced adenomas over 5 years was 21.3% of those taking placebo, 12.5% (P < 0.0001) of those taking low dose celecoxib and 15.8% (P < 0.0001) of those taking high-dose celecoxib. Investigator reported treatment emergent adverse events were similar across all treatment groups for categories including renal and hypertensive events and gastrointestinal ulceration and hemorrhage events. For a category composed of cardiovascular and thrombotic events, the risk relative to placebo was 1.6 (95% confidence interval, 1.0, 2.5) for those using 200 mg twice daily celecoxib and 1.9 (95% confidence interval, 1.2, 3.1) for those using 400 mg twice daily celecoxib. Secondary analysis showed an interaction between a baseline history of atherosclerotic heart disease and study drug use with respect to cardiovascular and thrombotic adverse events (P = 0.004). These results confirm the inhibitory effect of celecoxib on colorectal adenoma formation, and provide additional safety data indicating an elevated risk for cardiovascular and thrombotic adverse events, particularly for patients with preexisting atherosclerotic heart disease.
authors.affiliation: Brigham and Women's Hospital, Boston, MA 02115, USA. mbertagnolli@partners.org
authors.forename: Monica M
authors.initials: MM
authors.lastname: Bertagnolli
authors.forename: Craig J
authors.initials: CJ
authors.lastname: Eagle
authors.forename: Ann G
authors.initials: AG
authors.lastname: Zauber
authors.forename: Mark
authors.initials: M
authors.lastname: Redston
authors.forename: Aurora
authors.initials: A
authors.lastname: Breazna
authors.forename: Kyungmann
authors.initials: K
authors.lastname: Kim
authors.forename: Jie
authors.initials: J
authors.lastname: Tang
authors.forename: Rebecca B
authors.initials: RB
authors.lastname: Rosenstein
authors.forename: Asad
authors.initials: A
authors.lastname: Umar
authors.forename: Donya
authors.initials: D
authors.lastname: Bagheri
authors.forename: Neal T
authors.initials: NT
authors.lastname: Collins
authors.forename: John
authors.initials: J
authors.lastname: Burn
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Chung
authors.forename: Thomas
authors.initials: T
authors.lastname: Dewar
authors.forename: T Raymond
authors.initials: TR
authors.lastname: Foley
authors.forename: Neville
authors.initials: N
authors.lastname: Hoffman
authors.forename: Finlay
authors.initials: F
authors.lastname: Macrae
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Pruitt
authors.forename: John R
authors.initials: JR
authors.lastname: Saltzman
authors.forename: Bruce
authors.initials: B
authors.lastname: Salzberg
authors.forename: Thomas
authors.initials: T
authors.lastname: Sylwestrowicz
authors.forename: Ernest T
authors.initials: ET
authors.lastname: Hawk